Membership
The REMS Industry Consortium (RIC) brings together the Risk Evaluation and Mitigation Strategies industry to advance patient safety and innovation in the implementation of new drugs and biologics. By joining RIC, you can gain knowledge, experience, and professional affiliations that will put you at the forefront of REMS industry advancements. Through RIC networking opportunities, you will make vital connections with other professionals in this space who share your desire for collaboration and guidance in addressing industry challenges.
Membership dues for pharmaceutical manufacturers for 2026 are:
- Founding Members: $55,000
- Board Members (Board Seat and 5 or more participants from organization): $50,000
- Enterprise Members (5 or more participants from organization): $15,750
- Group Members (1-4 participants from organization): $5,250
Current RIC Members include:
- Amneal Pharmaceuticals
- Apellis Pharmaceuticals, Inc.
- Apotex
- Ascend Laboratories LLC, a subsidiary of Alkem Laboratories Ltd
- AstraZeneca Pharmaceuticals LP
- Avadel Pharmaceuticals
- Bristol Myers Squibb
- Compass Pathways
- Endo USA, Inc.
- Gilead Sciences
- GSK
- Hikma Pharmaceuticals USA Inc.
- Johnson & Johnson Innovative Medicine
- Jazz Pharmaceuticals
- Novartis
- Pfizer Inc.
- Regeneron
- Sandoz
- Sanofi
- Sun Pharma
- Takeda
- Tasman Pharma Inc.
- Teva Pharmaceuticals
- UCB, Inc.
- Viatris
Current Industry Partners include:
- APCER Life Sciences
- Axian Consulting, Ltd.
- ConnectiveRx
- Hawthorne Health
- Integrated Pharmacy Solutions
- Invaryant, LLC
- KPMG
- Maryann Major, Inc.
- MMS Holdings Inc
- MVG Consulting Services, Inc.
- Perspective Pharmacovigilance
- PPD, part of Thermo Fisher Scientific
- Shepherd Safety Services
- Syneos Health
- United BioSource, LLC
- Venebio Group, LLC